talquetamab
janssen
['monumental-1', 'multiplemyeloma', 'talquetamab']
#ash22 in the phase i/ii monumental-1 trial, #gprc5d-targeting bispecific antibody #talquetamab elicited rapid disease response in the majority of patients with heavily pretreated relapsed/refractory #multiplemyeloma 
A magazine from @ASH_Hematology offering news and views for the broader hematology/oncology community.